Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

NCT00596102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3258

Last updated 2014-07-30

Study results available
· View outcomes & findings →

Summary

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

Japanese Encephalitis purified inactivated vaccine

Japanese Encephalitis purified inactivated vaccine

Sponsors & Collaborators

  • Valneva Austria GmbH

    lead INDUSTRY

Principal Investigators

  • Evelyn Hatzenbichler, Ph.D. · Valneva Austria GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2011-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596102 on ClinicalTrials.gov